• Depot
  • Watchlist
  • Glocke
  • Handeln

    • PainReform News

    0,8101 $ -2,40% -0,0199 $
    In : 0,7576 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2QB4E
    ISIN: IL0011651580
    US-Symbol: PRFX
    Typ: Aktie

    PainReform News

    20.07.23 - PR Newswire
    Thinking about buying stock in Lumen Technologies, Mullen Automotive, Ballard Power Systems, Enovix, or PainReform?
    Thinking about buying stock in Lumen Technologies, Mullen Automotive, Ballard Power Systems, Enovix, or PainReform? PR Newswire
    14.07.23 - PR Newswire
    Thinking about buying stock in Virgin Galactic Holdings, TG Therapeutics, Lucid Group, Ainos, or PainReform?
    Thinking about buying stock in Virgin Galactic Holdings, TG Therapeutics, Lucid Group, Ainos, or PainReform? PR Newswire
    22.11.21 - PR Newswire
    Thinking about buying stock in Astra Space, PainReform, Vonage, Affimed NV, or Provention Bio?
    Thinking about buying stock in Astra Space, PainReform, Vonage, Affimed NV, or Provention Bio? PR Newswire
    22.07.21 - PR Newswire
    Thinking about buying stock in PainReform, Norwegian Cruise Line, Seres Therapeutics, CSX Corp, or Neptune Wellness Solutions?
    Thinking about buying stock in PainReform, Norwegian Cruise Line, Seres Therapeutics, CSX Corp, or Neptune Wellness Solutions? PR Newswire
    21.07.21 - PR Newswire
    Thinking about buying stock in TRxADE Health, Gevo, PainReform, Transocean, or Delta Air Lines?
    Thinking about buying stock in TRxADE Health, Gevo, PainReform, Transocean, or Delta Air Lines? PR Newswire
    04.01.21 - ACCESSWIRE
    PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
    Reports steady progress towards start of Phase 3 trial
    18.12.20 - PR Newswire
    Thinking about buying stock in Vistagen Therapeutics, Adapthealth, PainReform, Arbutus Biopharma, or AIM ImmunoTech?
    Thinking about buying stock in Vistagen Therapeutics, Adapthealth, PainReform, Arbutus Biopharma, or AIM ImmunoTech? PR Newswire
    23.11.20 - ACCESSWIRE
    PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
    HERZLIYA, ISRAEL / ACCESSWIRE / November 23, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-​stage specialty pharmaceutical company ...
    12.11.20 - ACCESSWIRE
    PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors
    HERZLIYA, ISRAEL / ACCESSWIRE / November 12, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-​stage specialty pharmaceutical company ...
    05.11.20 - ACCESSWIRE
    PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
    HERZLIYA, ISRAEL / ACCESSWIRE / November 5, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company ...
    19.10.20 - ACCESSWIRE
    PainReform Highlights Surgical Advantages of PRF-110
    Studies demonstrate unique benefits of PRF-100 beyond analgesic activity
    29.09.20 - ACCESSWIRE
    PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials
    HERZLIYA, ISRAEL / ACCESSWIRE / September 29, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company ...
    09.09.20 - ACCESSWIRE
    PainReform Announces Closing of $20.0 Million Initial Public Offering
    HERZLIYA, ISRAEL / ACCESSWIRE / September 9, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »